EIB

DPG Media operates as a media company. The Company provides wide range of news such as entertainment, sports, politics, market, and other related stories, as well as offers advertising services. DPG Media serves customers in Belgium.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

EclecticIQ B.V. is a global provider of threat intelligence, hunting, and response technology, supporting government organizations and commercial enterprises in enhancing their cybersecurity posture. Founded in 2014 and headquartered in Amsterdam, with additional offices in Herndon, Virginia; London, United Kingdom; and Chi?inau, Moldova, the company offers a range of products and services. These include the EclecticIQ Platform, a comprehensive threat intelligence platform; the EclecticIQ Fusion Center, which delivers multi-source threat intelligence bundles; and the EclecticIQ Academy for cyber threat intelligence training. The company also provides consulting services, team collaboration tools, and various integrations to optimize incident response and security controls. With a focus on building defenses against emerging threats, EclecticIQ has expanded its capabilities through acquisitions, such as Polylogyx's endpoint technology, to further enhance its offerings for clients facing sophisticated cyber threats.

Inbiose NV researches, develops, and produces specialty carbohydrates and related products. It develops fermentation based technology platform suitable for the industrial manufacturing of specialty carbohydrate, called glycans, and produces human milk oligosaccharides (HMO, fucosylated, and sialylated oligosaccharides), infant nutrition, probiotics nutraceuticals, and cosmetic products that helps immune defenses, brain development, gastro-intestinal disorder, anti-microbial and viruses defence mechanisms. The company produces specialty carbohydrates and sugars, such as L-fucose, L-ribose, and sialic acid or human milk oligosaccharides such as fucosyllactose, and sialyllactose; human milk bioactives also called Human Milk Oligosaccharides (HMO), for infant food formula (milk bioactives), fortified and functional food/beverages, health ingredients for human and animal, and over the counter food supplements; and prebiotics and probiotics. It also offers biological system feasibility studies (strain construction and proof of concept); development of upstream fermentation protocols and scale-up for specialty carbohydrate targets through access to pilot plant facilities; fermentation optimization (strain platform screening); downstream process design and development; and research contracts and manufacturing contracts. The company serves human and animal nutraceuticals, biomedical, and agro industries. It has partnership with private or public institutions, KOLs in scientific and life science communities, industrial/medical food manufacturers, pharmaceutical companies, and animal or plant health companies in form of licensing-out, licensing-in, co-development, contract manufacturing, and third party services. The company was founded in 2013 and is based in Ghent, Belgium.

Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Utilizing the Company's unique knowledge of the bone/joint physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored in-house production methods, and minimally invasive treatment techniques.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

ISA Pharmaceuticals B.V. is a clinical-stage immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent virus infections. The Company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and its AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defense mechanisms towards fighting the disease, either alone or in combination with existing therapies.

The Medical Credit Fund is a non-profit health investment fund. It supports private healthcare facilities in Africa obtaining capital to strengthen and upgrade their operations in order to enhance access to affordable quality healthcare.

October SA is a lending platform designed for small and medium-sized enterprises (SMEs), facilitating direct borrowing from individual and institutional lenders. Established in France in 2014 under the name Lendix, the company rebranded to October SA in 2018. It operates as a pan-European platform with locations in France, Spain, Italy, and the Netherlands. By simplifying access to funding, October aims to empower businesses and enhance their growth potential. The platform emerged in response to regulatory changes that allowed increased competition in the lending sector, effectively democratizing financial resources for SMEs across Europe.

Ultimaker B.V., founded in 2011 and headquartered in Utrecht, the Netherlands, is a prominent developer of 3D printers and associated software tools. The company's product range includes models like the Ultimaker 3, Ultimaker 2+, and Ultimaker S5, catering to various applications such as prototyping, manufacturing, research, and education. Ultimaker is recognized for its open-source approach, fostering collaboration with its community to enhance innovation in the Maker industry. In addition to hardware, the company offers software solutions like Ultimaker Cura and Ultimaker Connect, which assist users in preparing 3D models for printing and managing their printers. With additional offices in the USA and Singapore, Ultimaker aims to facilitate a transition towards local and digital manufacturing, making 3D printing accessible and effective for professional designers and engineers.

Enevo Oy develops the Enevo, an analytic software that collects and analyzes data points to measure waste and recycling generation. It provides a waste management analytics solution that uses ultrasonic sonar technology to detect fill levels for commercial clients, haulers, and cities. The company offers insights to clients handling waste contracts to streamline their waste management operations. It serves customers through resellers in the Netherlands, Belgium, Norway, and other countries in Europe. Enevo Oy was incorporated in 2010 and is headquartered in Espoo, Finland with additional offices in the United States, the United Kingdom, Germany, and Japan.

Qredits is a financial institution that supports both aspiring and established entrepreneurs in successfully launching and managing their businesses. It specializes in providing microfinancing solutions, including commercial loans and microcredit, with amounts reaching up to €250,000. In addition to financial assistance, Qredits offers personal coaching and a range of entrepreneurial tools aimed at fostering business growth and innovation. The organization emphasizes a forward-looking approach, focusing on the potential of good ideas and the strength of entrepreneurship to turn dreams into reality. Through its mentoring and educational programs, Qredits aims to empower micro-entrepreneurs and stimulate the growth of small and medium-sized enterprises in the Netherlands.